Cargando…
Role of lipoprotein(a) in plaque progression
Identified by Berg in 1963, lipoprotein(a) represents a key contemporary residual risk pathway in atherosclerotic cardiovascular disease (ASCVD) secondary prevention. Indeed, epidemiological and genetic studies have undoubtedly demonstrated that lipoprotein(a) is one of the strongest causal risk fac...
Autores principales: | Ruscica, Massimiliano, Rizzuto, Alessandra S, Corsini, Alberto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653156/ https://www.ncbi.nlm.nih.gov/pubmed/36380804 http://dx.doi.org/10.1093/eurheartjsupp/suac071 |
Ejemplares similares
-
Hypocholesterolaemic treatment in coronary unit: from statins to anti PCSK9 therapies and bempedoic acid
por: Ferri, Nicola, et al.
Publicado: (2023) -
Reduction of cerebrovascular and peripheral events with PCSK9 inhibitors: Does it just depend on the lowering of the low-density lipoprotein?
por: Cesaro, Arturo, et al.
Publicado: (2022) -
Genetics and clinics: together to diagnose cardiomyopathies
por: Urtis, Mario, et al.
Publicado: (2022) -
Post-infarct mitral insufficiency: when to resort to reparative surgery, when to the mitral clip
por: Gomez-Polo, Juan Carlos, et al.
Publicado: (2022) -
On site cardiac surgery for structural heart interventions: a fence to mend?
por: Foglietta, Melissa, et al.
Publicado: (2022)